Why Life Science Patents Usually Face A Restriction Requirement
Summary
- A restriction requirement occurs when the USPTO determines that a patent application claims multiple independent and distinct inventions.
- Life science patent applications frequently receive restriction requirements because they often contain multiple species, compounds, methods, and formulations.
- Biotechnology applications involving antibodies, proteins, nucleic acids, and Markush claim structures are particularly susceptible to restriction practice.
- Restriction requirements do not indicate a lack of patentability and can create opportunities for future divisional applications.
- Strategic responses to restriction requirements can help applicants build stronger and more comprehensive patent portfolios.
Introduction
Life science patent applications are more likely than many other technologies to receive a restriction requirement from the United States Patent and Trademark Office (USPTO). While inventors are often surprised when an examiner requires them to choose between different claim groups, restriction practice is a common part of biotechnology, pharmaceutical, medical device, and diagnostic patent prosecution.
Understanding why a restriction requirement occurs can help applicants develop a filing strategy that preserves valuable intellectual property rights while minimizing unnecessary costs during the patent prosecution process.
What Is a Restriction Requirement?
A restriction requirement is a procedural action issued by a USPTO examiner when an application claims two or more independent and distinct inventions. The examiner may require the applicant to elect one invention for examination while withdrawing the non-elected claims from consideration.
The USPTO’s position is that examining multiple distinct inventions in a single application would create an unreasonable examination burden. As a result, the examiner can require the applicant to select one invention and pursue the others later through divisional applications.
Importantly, a restriction requirement does not mean the invention lacks patentability. Instead, it concerns how the claims are organized and examined.
Why Life Science Applications Frequently Receive Restriction Requirements
Life science inventions often involve complex technologies with multiple layers of innovation. A single research project may produce:
- New compounds
- Pharmaceutical formulations
- Methods of treatment
- Methods of manufacture
- Diagnostic methods
- Genetic constructs
- Engineered cells
- Research tools
Inventors frequently attempt to protect all of these innovations in a single patent application. While this approach may be commercially sensible, it also increases the likelihood that the examiner will conclude that multiple distinct inventions are being claimed.
For companies developing biologics, pharmaceuticals, diagnostics, or other biological technologies, restriction practice is often a routine aspect of securing protection for biological patents and other life science innovations.
Large Numbers of Species
Biotechnology applications often disclose numerous variants of a biological molecule, such as:
- Antibodies
- Proteins
- Nucleic acids
- Cell lines
- Engineered microorganisms
An examiner may determine that these variants represent distinct species and issue a restriction requirement requiring election of one species or subgroup.
For example, an antibody application may disclose dozens or hundreds of candidate antibodies targeting the same antigen. The examiner may require the applicant to elect a representative species for examination.
Product and Method Claims
Life science applications commonly include both product claims and method claims.
Examples include:
- A therapeutic protein
- A pharmaceutical composition containing the protein
- A method of treating disease using the protein
- A method of manufacturing the protein
Although these claims may be commercially related, examiners frequently separate them into different invention groups depending on the facts of the application.
Markush Group Complexity
Chemical and biotechnology applications often use broad Markush claim language covering numerous alternatives. Examiners may conclude that the alternatives are sufficiently distinct to justify restriction.
The larger and more diverse the claimed genus becomes, the greater the likelihood of a restriction requirement. Applicants unfamiliar with these claim structures may benefit from understanding Markush structures in patents, which are commonly used in chemical and biotechnology applications.
Common Restriction Scenarios in Biotechnology
Several restriction patterns appear repeatedly in life science prosecution.
Species Restriction
The examiner requires election of one species from multiple disclosed species.
Examples include:
- Different antibodies
- Different nucleic acid sequences
- Different protein variants
- Different chemical compounds
Product Versus Process Restriction
The examiner separates claims directed to:
- A biological product
- Methods of making the product
Product Versus Method of Use Restriction
The examiner separates:
- Claims directed to a therapeutic compound
- Claims directed to treating a disease with the compound
This issue frequently arises in applications involving biologics and therapeutic molecules.
Combination Versus Subcombination Restriction
The examiner separates a larger system from individual components that may have independent utility.
This situation can arise in medical device and diagnostic technology applications.
Is a Restriction Requirement Bad?
Not necessarily.
Although restriction requirements can increase prosecution costs, they also create opportunities.
When claims are divided into separate applications, applicants may obtain multiple patents covering different aspects of the technology. Divisional applications can also extend patent portfolio development over time as commercial priorities become clearer.
For many companies, especially those developing biologics or platform technologies, a restriction requirement can ultimately support broader patent strategies for biologics and molecules by allowing different aspects of the invention to be pursued separately.
Additionally, divisional applications filed in response to a restriction requirement generally benefit from statutory protections against certain double-patenting concerns.
How Applicants Should Respond
When responding to a restriction requirement, applicants should carefully evaluate:
- Which invention group provides the strongest immediate commercial protection
- Which claims are most likely to be allowed
- Whether future divisional applications may be desirable
- Budget considerations and portfolio objectives
In some situations, it may be appropriate to traverse the restriction requirement if the examiner’s grouping appears improper. In many cases, however, applicants elect a claim group while preserving rights to pursue the remaining subject matter later.
Because the election decision can affect future patent coverage, applicants should consider both legal and business objectives before responding.
Strategic Considerations for Life Science Companies
Life science technologies often evolve through years of research, regulatory development, and commercialization. A restriction requirement can provide a roadmap for building a layered patent portfolio covering:
- Core biological compositions
- Manufacturing technologies
- Treatment methods
- Diagnostic applications
- Follow-on improvements
For innovators developing therapies, diagnostics, and clinical-stage biologics, restriction practice often becomes an important component of broader biotechnology intellectual property strategies.
Rather than viewing a restriction requirement as a setback, many companies use it as an opportunity to create multiple patent assets from a single disclosure. This approach can also complement a broader IP portfolio strategy designed to protect different aspects of a technology over time.
Conclusion
A restriction requirement is especially common in life science patent applications because biotechnology and pharmaceutical inventions frequently contain multiple species, products, methods, and related innovations. The USPTO may require applicants to elect one invention for examination while reserving others for future divisional applications.
Understanding restriction practice early in the patent process can help inventors and companies develop stronger filing strategies, preserve valuable intellectual property rights, and maximize long-term patent protection. Working with an experienced biotechnology patent attorney can help applicants navigate restriction practice and make strategic decisions that align with their commercial goals.
About
Attorney Collier started his own law firm straight out of law school and has been practicing law in Ohio for 5+ years. During that time, Joe focused on business law and litigation, gaining some exposure to intellectual property law. While running his firm in 2021, Joe decided to go back to school and get his patent license. Since then, Attorney Collier has been focusing on protecting innovators and entrepreneurs through his expertise in intellectual property and business law.